Is It Time To Reconsider Labcorp (LH) After Strong Healthcare Sector Coverage And DCF Upside?
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
If you are wondering whether Labcorp Holdings is priced attractively right now, starting with a clear look at its valuation can help you decide how it fits into your portfolio.
The stock recently closed at US$289.12, with reported returns of 2.3% over 7 days, 6.5% over 30 days, 14.9% year to date, 16.4% over 1 year, 45.9% over 3 years, and 48.5% over 5 years.
Recent news coverage has focused on Labcorp Holdings’ position in the healthcare sector and how its testing and diagnostics capabilities fit into broader industry trends. This context is important when you interpret the share price moves, because it shapes how investors think about the company’s long term role in medical testing and related services.
On our valuation checks, Labcorp Holdings currently records a value score of 4/6. This sets up a closer look at how it stacks up across different valuation methods and hints at an even richer way to think about fair value that we will come back to at the end of this article.
A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting future cash flows and discounting them back to the present.
For Labcorp Holdings, the latest trailing twelve month Free Cash Flow is about $1.15b. The model used here is a 2 Stage Free Cash Flow to Equity approach, which incorporates an explicit forecast period and then longer term projections.
Simply Wall St has projections in place for the next decade, with estimated Free Cash Flow in 2035 of about $1.55b. These longer term forecasts extend beyond typical analyst coverage, so the later years are extrapolated rather than based on individual analyst line items.
Putting these projections together and discounting them back results in an estimated intrinsic value of about $390.50 per share for Labcorp Holdings. Compared with the recent share price of US$289.12, this DCF output suggests the shares trade at roughly a 26.0% discount on this model.
For a profitable business like Labcorp Holdings, the P/E ratio is a practical way to think about value because it links what you pay today to the earnings the company is already generating. In general, higher growth expectations and lower perceived risk can justify a higher P/E, while slower growth or higher risk usually point to a lower, more conservative P/E being reasonable.
Labcorp currently trades on a P/E of 27.18x. That sits above the broader Healthcare industry average of 23.65x, but below the peer average of 32.83x. Simply Wall St also calculates a proprietary “Fair Ratio” of 31.28x for Labcorp, which reflects factors such as its earnings profile, profit margins, industry, market capitalization and specific risk characteristics.
This Fair Ratio aims to be more tailored than a simple comparison with industry or peer averages, because it adjusts for company specific traits rather than assuming all Healthcare stocks deserve the same multiple. Comparing the Fair Ratio of 31.28x with the current P/E of 27.18x suggests the shares are pricing in a lower multiple than this model implies.
Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St’s Community page you can use Narratives, where you set out your own story for Labcorp Holdings by linking assumptions about its future revenue, earnings and margins to a financial forecast and fair value. You can then compare that fair value to the current share price to decide whether you see it as a buy or a sell candidate. The system updates your Narrative automatically when new news or earnings arrive. For example, one investor might build a Narrative around Alzheimer’s and cancer testing progress and land near the higher US$325 fair value, while another might focus on tariffs, regulatory changes and competitive pressures and sit closer to the lower US$260 figure.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
